Shandong Kexing Bioproducts Co. Ltd. A
Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia. The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral ther… Read more
Market Cap & Net Worth: Shandong Kexing Bioproducts Co. Ltd. A (688136)
Shandong Kexing Bioproducts Co. Ltd. A (SHG:688136) has a market capitalization of $808.90 Million (CN¥5.94 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #11557 globally and #2753 in its home market, demonstrating a 2.54% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shandong Kexing Bioproducts Co. Ltd. A's stock price CN¥29.49 by its total outstanding shares 201257250 (201.26 Million).
Shandong Kexing Bioproducts Co. Ltd. A Market Cap History: 2020 to 2026
Shandong Kexing Bioproducts Co. Ltd. A's market capitalization history from 2020 to 2026. Data shows change from $1.11 Billion to $808.90 Million (-5.99% CAGR).
Shandong Kexing Bioproducts Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shandong Kexing Bioproducts Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.43x
Shandong Kexing Bioproducts Co. Ltd. A's market cap is 0.43 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
19.05x
Shandong Kexing Bioproducts Co. Ltd. A's market cap is 19.05 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.11 Billion | $1.22 Billion | $139.14 Million | 0.91x | 8.01x |
| 2021 | $772.85 Million | $1.29 Billion | $96.46 Million | 0.60x | 8.01x |
| 2022 | $588.09 Million | $1.32 Billion | -$90.30 Million | 0.45x | N/A |
| 2023 | $555.45 Million | $1.26 Billion | -$190.29 Million | 0.44x | N/A |
| 2024 | $599.61 Million | $1.41 Billion | $31.48 Million | 0.43x | 19.05x |
Competitor Companies of 688136 by Market Capitalization
Companies near Shandong Kexing Bioproducts Co. Ltd. A in the global market cap rankings as of March 18, 2026.
Key companies related to Shandong Kexing Bioproducts Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Shandong Kexing Bioproducts Co. Ltd. A Historical Marketcap From 2020 to 2026
Between 2020 and today, Shandong Kexing Bioproducts Co. Ltd. A's market cap moved from $1.11 Billion to $ 808.90 Million, with a yearly change of -5.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥808.90 Million | -6.88% |
| 2025 | CN¥868.69 Million | +44.88% |
| 2024 | CN¥599.61 Million | +7.95% |
| 2023 | CN¥555.45 Million | -5.55% |
| 2022 | CN¥588.09 Million | -23.91% |
| 2021 | CN¥772.85 Million | -30.63% |
| 2020 | CN¥1.11 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Shandong Kexing Bioproducts Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $808.90 Million USD |
| MoneyControl | $808.90 Million USD |
| MarketWatch | $808.90 Million USD |
| marketcap.company | $808.90 Million USD |
| Reuters | $808.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.